Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02557516 · ClinicalTrials.gov registry record · Phase 1
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
A Phase 1 study, sponsored by Innate Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02557516 is a Phase 1 study that was terminated before completion, run by Innate Pharma. The registered enrollment target is 22 participants.
The verdict
NCT02557516, a Phase 1 study, was terminated before completion, sponsored by Innate Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Combination study of monalizumab (IPH2201) with Ibrutinib in relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia (CLL) patients in 2 parts : * phase 1 : a 3+3 design to assess the Maximum Tolerated Dose (MTD) * phase 2: to evaluate the anti-leukemic activity of the combination
Interventions
- DRUG monalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-11-09 |
| Est. Completion | 2019-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02557516
The ClinicalTrials.gov registry entry for NCT02557516 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monalizumab is the first listed.
NCT02557516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02557516 about?
NCT02557516 is a clinical study titled "Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL". Combination study of monalizumab (IPH2201) with Ibrutinib in relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia (CLL) patients in 2 parts : * phase 1 : a 3+3 design to assess the Maximum Tolerated Dose (MTD) * phase 2: to evaluate the anti-leukemic activity of the combination
What is the current status of trial NCT02557516?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-11-09. Estimated completion is 2019-09-25.
What interventions are being tested in trial NCT02557516?
The interventions under investigation include: monalizumab (DRUG).
Who is sponsoring clinical trial NCT02557516?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.